Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2

US9296747B1 · kind B1 · utility

Assignee

• Allergan, Inc. · US

Inventors

• Julie A. Wurster · Irvine, US
• Thomas C. Malone · Irvine, US
• Clarence Eugene Hull, III · Mission Viejo, US
• Sandhya Rao · Irvine, US
• Rong Yang · Boston, US
• Richard C. Yee · Tustin, US

Key dates

• Filing date: Oct 10, 2014
• Grant date: Mar 29, 2016
• Expiry date: Oct 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.